• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Sector
    / Unipharm


    Active Ingredient *
    Sacubitril 24 mg, 49 mg, 97mg
    Valsartan 26 mg, 51 mg, 103 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Film Coated Tablets

    28 x 50 mg

    partial basket chart

    Film Coated Tablets

    56 x 50 mg

    partial basket chart

    Film Coated Tablets

    28 x 100 mg

    partial basket chart

    Film Coated Tablets

    56 x 100 mg

    partial basket chart

    Film Coated Tablets

    56 x 200 mg

    partial basket chart

    Dosage

    The usual starting dosage is generally one tablet of 50 mg or 100 mg twice a day. The recommended target dosage is generally 200 mg twice a day.


    Indications

    Treatment of heart failure (NYHA class II-IV) in patients with systolic dysfunction.
    This medicinal product has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ACE) inhibitor therapy.


    Contra-Indications

    * Hypersensitivity to the active substances or to any of the excipients.
    * Concomitant use with ACE inhibitor. Wait 36 hours after taking the last ACEI dose before starting treatment with this medical product.
    * Known history of angioedema related to ACE inhibitor or an angiotensin receptor blocker (ARB) therapy, hereditary or unknown cause.
    * Concomitant use with aliskiren-containing medicinal products in patients with diabetes mellitus or in patients with renal impairment.
    * Severe liver disease.
    * Second and third trimester of pregnancy.


    Special Precautions

    Please refer to the license holder for further details.


    Side Effects

    Very common: Cough, dizziness, diarrhea, low levels of red blood cells, tiredness, acute renal failure, hypokalemia, headache, fainting, weakness, nausea, orthostatic hypotension, gastritis, spinning sensation, hypoglycemia.
    Common:
    Hypotension, hyperkalemia, renal impairment.
    Please refer to the license holder for further details.


    Drug interactions

    Please refer to the license holder for further details.


    Pregnancy and Lactation

    Please refer to the license holder for further details


    Overdose

    Please refer to the license holder for further details


    Manufacturer
    Unipharm Ltd.
    CLOSE